CLAIMS

1. Use of semaglutide in the manufacture of a medicament for weight management of a subject in need thereof, wherein said semaglutide is to be administered subcutaneously to said subject in an amount of 2.2 - 2.7 mg per week.

2. The use according to claim 1, wherein said weight management is chronic weight management.

3. The use according to any one of the preceding claims, wherein said weight management is selected from the group consisting of: reducing body weight, treating and/or preventing obesity, treating and/or preventing overweight, and preventing weight gain.

4. The use according to any one of the preceding claims, wherein said weight management is treating and/or preventing obesity.

5. The use according to any one of the preceding claims, wherein said weight management is treating and/or preventing overweight.

6. The use according to any one of the preceding claims, wherein said semaglutide is to be administered in an amount of 2.2 - 2.6 mg per week.

7. The use according to any one of the preceding claims, wherein said semaglutide is to be administered in an amount of 2.3-2.5 mg per week.

8. The use according to any one of the preceding claims, wherein said semaglutide is to be administered per week is selected from the group consisting of 2.2 mg, 2.3 mg, 2.4 mg, 2.5 mg, 2.6 mg, and 2.7 mg.

9. The use according to any one of the preceding claims, wherein said semaglutide is to be administered in an amount of 2.4 mg per week.

10. The use according to any one of the preceding claims, wherein semaglutide is to be administered for 52 weeks.

11. The use according to any one of the preceding claims, wherein said semaglutide is to be administered via subcutaneous injection.

12. The use according to any one of the preceding claims, wherein semaglutide is to be administered in the form of a composition further comprising one or more pharmaceutically acceptable excipients.

13. The use according to any one of the preceding claims, wherein said composition is in the form of a solution or a suspension, such as an aqueous solution.

14. The use according to any one of the preceding claims, wherein the pH of said composition is in the range of 6.0-10.0, such as 6.5-9.0 or 7.0-8.0.

15. The use according to any one of the preceding claims, wherein the pH of said composition is about 7.4.

16. The use according to any one of the preceding claims, wherein the concentration of semaglutide in said composition is 0.01-50 mg/ml, such as 0.05-20 mg/ml or 0.1-10 mg/ml.

17. The use according to any one of the preceding claims, wherein the concentration of semaglutide in said composition is 0.01-5 mg/ml, such as 0.05-2 mg/ml.

18. The use according to any one of the preceding claims, wherein said subject has at least one weight-related comorbid condition selected from the group consisting of hypertension, type 2 diabetes mellitus, dyslipidemia, sleep apnoea, and urine incontinence.

19. The use according to any one of the preceding claims, wherein said subject has type 2 diabetes.